Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Trial to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

NCT02576496 is registered in ClinicalTrials.gov with Mundipharma Research Limited as lead sponsor.

NCT NCT02576496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02576496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Trial to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
Lead sponsor
Mundipharma Research Limited
Phase
Phase 1
Overall status
Completed
Start date
April 14, 2016
Completion date
November 21, 2023
Enrollment
106 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous t cell lymphoma, hematological malignancies, hodgkin's lymphoma, multiple myeloma